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Abstract
Background: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to
increase access to treatment. Direct-acting antiviral (DAA) treatment can be provided in primary healthcare services
(PHCS), improving accessibility, and, potentially, retention in care. Here, we describe our protocol for assessing the
effectiveness of providing DAAs in PHCS, and the impact on the HCV care cascade. In addition, we reflect on the
challenges of conducting a model of care study during a period of unprecedented change in HCV care and treatment.
Methods: Consenting patients with HCV infection attending 13 PHCS in Australia or New Zealand are randomized to
receive DAA treatment at the local tertiary institution (standard care arm), or their PHCS (intervention arm). The primary
endpoint is the proportion commenced on DAAs and cured. Treatment providers at the PHCS include: hepatology
nurses, primary care practitioners, or, in two sites, a specialist physician. All PHCS offer opioid substitution therapy.
Discussion: The Prime Study is the first real-world, randomized, model of care study exploring the impact of community
provision of DAA therapy on HCV-treatment uptake and cure. Although the study has faced challenges unique to this
period of time characterized by changing treatment and service delivery, the data gained will be of critical importance in
shaping health service policy that enables the elimination of HCV.
Trial registration: ClinicalTrials.gov, ID: NCT02555475. Registered on 15 September 2015.
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Background
Globally, approximately 71 million people have hepatitis
C virus (HCV) infection, and each year 700,000 people
die from HCV-related liver disease [1, 2]. The most
common mode of HCV transmission in developed coun-
tries and increasingly in developing countries, is shared
use of injecting equipment by people who inject drugs
(PWID) and, therefore, the burden of disease is borne by
current or former PWID [3]. Until 2014, the HCV care
cascade demonstrated that few people completed diag-
nostic tests and received treatment [4, 5]. Treatment
was only available from specialists in tertiary hospitals,
where the need for a referral, inflexible appointment
scheduling and lack of multidisciplinary care functioned
as a barrier. Further barriers included: the toxicity and
variable efficacy of pegylated interferon (PEG)-based
therapy, the stigma experienced in healthcare settings
and, historically, the need for a liver biopsy [6].
In the era of PEG-based therapy for HCV, many novel
models of care were piloted in an attempt to increase the
number of people commencing treatment. Strategies in-
cluded: diversification of care providers to include specialist
nurses, or primary care practitioners who had undertaken
special training, expanding modes of interaction beyond
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face-to-face to include telephone or videoconference-based
appointments, and offering care outside of tertiary hospitals
in venues such as community drug and alcohol services
and prisons [7–10]. The impact of these programs was
curtailed by PEG-associated toxicity and the limited efficacy
of PEG-based therapy.
The discovery of highly efficacious, well-tolerated
direct-acting antiviral (DAA) therapy for HCV has revo-
lutionized the treatment landscape, and has allowed
innovative models of care to develop in order to improve
the HCV care cascade. Globally, multiple treatment
models have been implemented and evaluated in re-
sponse to local DAA funding and prescribing require-
ments [11–13]. In Australia, since 1 March 2016 and in
New Zealand since 1 October 2016, all primary care
practitioners have been encouraged to prescribe DAAs,
in consultation with a specialist physician if required
[14]. All models are attempting to increase the number
of people that are treated and cured, especially in prior-
ity populations such as PWID, in order to reduce inci-
dence [15]. Given that treatment access policies around
the world are currently highly divergent, it is important
to obtain data to determine which models of care are
most effective and cost-effective at increasing treatment
uptake, with the ultimate aims of reducing transmission
and preventing morbidity and mortality from HCV.
Some observational studies have reported improve-
ments in retention in care and treatment uptake with
the provision of multidisciplinary care to people who
have chronic HCV [13, 16]. Further observational data
supports HCV care and treatment in the community,
usually in a facility with which the patient is already en-
gaged [8, 10, 12, 17]. One small, randomized study of 21
patients suggested that treatment uptake of directly ob-
served PEG therapy was higher in a community treat-
ment center when compared to a tertiary hospital [18].
There is no study that directly compares the difference
in retention in care, uptake of DAA treatment and cure
outcome, if care and treatment is provided in the commu-
nity, compared to at a tertiary hospital service. To investi-
gate the effect of community-based HCV treatment on
the care cascade, we have designed the Prime Study – to
determine the impact of providing DAA treatment in the
community on treatment uptake, and to directly compare
tertiary hospital and community cure outcomes.
Methods
Study design
The Prime Study is an open-label, non-blinded, ran-
domized controlled, effectiveness and implementation
study. We initially aimed to recruit and randomly allo-
cate 380 participants. We selected an effectiveness
study design to enable comparison of the impact of
community treatment on DAA treatment uptake
across the two study arms, and simultaneously a
non-inferiority study design to assess the effectiveness
of community-based DAA treatment relative to an his-
torical control group of people treated with PEG-based
therapy. This study’s hybrid design combines testing
effects of a clinical intervention on relevant outcomes
whilst observing and gathering information on imple-
mentation [19]. The study protocol (version 7, 23
February 2017) follows the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
Statement, see Additional file 1 (http://www.spirit-sta-
tement.org/). This trial has been registered at Clinical-
Trials.gov (ID: NCT02555475).
Study objectives
The primary objective of the study is:
1. To estimate the proportion of people with HCV
attending a primary healthcare service (PHCS) who
commence DAA treatment at the PHCS and are
cured; as measured by sustained virologic response
rates 12 weeks post treatment (SVR12)
Secondary objectives are:
2. To estimate the difference in the proportion of
people with HCV infection attending a PHCS who
commence DAA treatment if they are managed at
their PHCS, compared to those who are referred to
and managed at a tertiary hospital
3. To estimate the difference in the proportion of
people with HCV infection attending a PHCS who
obtain an SVR12 if they are managed at their
PHCS, compared to those who are referred to, and
managed at, a tertiary hospital
4. To define the cascade of care for patients referred
to a community hepatitis nurse for assessment of
HCV
5. To estimate the reduction in HCV prevalence and
corresponding epidemiological impact if service
delivery through PHCS was scaled up nationally
6. To estimate the cost-effectiveness of managing and
treating people in a PHCS compared to a tertiary
hospital
Study setting
This study is being conducted in Australia (Melbourne
and Geelong) and New Zealand (Auckland and Christ-
church). Community hepatitis nurses are employed by
tertiary hospitals to work in PHCS in the community,
providing an outreach service. All PHCS that the com-
munity hepatitis nurses attend provide opioid substitu-
tion therapy (OST), and many provide a variety of other
services, i.e., needle and syringe distribution, and drug
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and alcohol counseling. In November 2015, eight PHCS
affiliated with three tertiary hospital services in Victoria
began recruitment. The Australian pharmaceutical bene-
fits scheme (PBS) listing of DAAs on 1 March 2016 cre-
ated a significant barrier for recruitment; therefore, the
study was expanded, and a further five PHCS affiliated
with two tertiary hospital services in New Zealand com-
menced recruitment in February 2017. The New Zealand
Government has funded DAAs for people with a MELD
< 15 only for genotype (Gt) 1 HCV, and, therefore, re-
cruitment in New Zealand was limited to patients with
Gt 1 infection.
Study intervention
After consent has been obtained (see patient informed
consent form, Additional file 2), the community hepatitis
nurse performs initial screening and participants are
randomized into one of two arms, as outlined below (see
Fig. 1).
Group 1 (standard tertiary care arm)
Participants with chronic HCV infection are referred for
12 weeks of DAAs treatment under the care of specialist
physicians (gastroenterologists, hepatologists and infec-
tious diseases physicians) at the local tertiary hospital
Group 2 (intervention PHCS arm)
Participants with chronic HCV infection receive
12 weeks of DAA treatment under the care of nursing
and medical staff at their PHCS
Randomization
Although patients are randomized at the end of the
screening visit, a unique feature of this study is that
randomization occurs before all screening procedures
are complete. This is because pre-treatment assessment,
which consists of blood tests and transient elastography
(TE) (FibroScan®, Echosens), is a key part of the care
cascade, and given that TE is not readily available in
Australia or Auckland, in these study sites the location
of TE is determined by the randomization result (see
Fig. 1a). In Christchurch, TE is readily available in the
community, and participants undergo TE at their PHCS
as part of the screening visit (see Fig. 1b).
Participants are randomized to the two study arms
using a block randomization approach. Randomization
occurs at the PHCS level, to ensure equal numbers of
patients from each PHCS are randomized to each arm.
Random sequences of permuted blocks are generated,
with each block allocating six study participants in a bal-
anced fashion across treatment groups. Randomization
is programmed using Stata version 13.0 and provided to
study staff in sealed envelopes (Australian sites) or via
REDCap database (New Zealand sites).
After the pre-treatment assessment has been com-
pleted, the results are reviewed in a follow-up appoint-
ment located at the tertiary hospital for group 1, and the
PHCS for group 2. Eligible patients are then able to
commence DAA treatment.
Study medications, dosage and administration
The medications being used for this study require a
12-week course of oral therapy.
Participants with genotype 1 are commenced on: pari-
taprevir 75 mg /ritonavir 50 mg/ombitasvir 12.5 mg
co-formulated in one tablet, two tablets in the morning
with food and dasabuvir 250 mg one tablet twice daily
with food. For genotype 1a weight-based ribavirin was
added: ≤ 75 kg 1000 mg daily in two divided doses or ≥
75 kg 1200 mg daily in two divided doses.
Participants with genotype 3 are commenced on:
sofosbuvir 400 mg one tablet daily and daclatasvir 60 mg
one tablet orally daily.
Participants with genotype 4 are commenced on: pari-
taprevir 75 mg /ritonavir 50 mg ombitasvir 12.5 mg
co-formulated in one tablet, two tablets in the morning
with food and weight-based ribavirin as above.
In Australia, treatment medication is dispensed ac-
cording to the randomization group. Participants ran-
domized to group 1 fill their scripts at the tertiary
hospital pharmacy. Participants randomized to group 2
fill their scripts at a community pharmacy, or have their
medications delivered to their PHCS by their community
hepatitis nurse. In New Zealand, treatment medication is
dispensed according to local practice, which includes
some tertiary hospital prescriptions being dispensed from
community pharmacies. Participants self-administer the
combination therapy.
Eligibility and recruitment
Recruitment
Recruitment is undertaken by the community hepatitis
nurses at each study site.
Eligibility
Participants must be:
1. Aged over 18 years old; and
2. Able to provide written informed consent; and
3. Have evidence of chronic HCV infection Gt 1a, Gt
3, or Gt 4; and
4. Not known to have cirrhosis as defined by; a liver
biopsy within 24 months prior to screening
demonstrating the absence of cirrhosis, or a
screening TE reading < 12.5 kPab, or, if TE is
unsuccessful, a screening aspartate aminotransferase
to platelet ratio index (APRI) < 1.0 and no clinical
or laboratory evidence of cirrhosis; and
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5. Be HCV treatment naïve or have previous exposure
to PEG / ribavirin therapy only
aNZ sites will only recruit Gt 1 participants.
bWhen the study commenced recruitment in Novem-
ber 2015 the initial screening TE was < 9.5 kPa to ex-
clude anyone with advanced fibrosis (METAVIR stages
F3–F4). This was increased to < 12.5 kPa on 1 March
2016, to align with the Australian Consensus Statement
on HCV treatment that patients without cirrhosis
(METAVIR stage F4) can receive community-based
treatment [14].
Study subjects are permitted to have elevated ala-
nine aminotransferase (ALT) and AST levels up to
10 times the upper limit of normal, but all of the
following parameters have to fall within normal
limits as reported by the laboratory: hemoglobin,
platelet count, INR, albumin, and direct bilirubin. A
creatinine clearance greater than 60 ml/min was
required.
a
b
Fig. 1 Screening process, eligibility and randomization in the Australian and Auckland sites (a) and the Christchurch site (b)
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Exclusion criteria included (1) known cirrhosis, as de-
fined above, (2) prior exposure to DAA protease inhibi-
tors, (3) HIV or hepatitis B co-infection, (4)
hepatocellular carcinoma, (5) pregnancy or breastfeed-
ing, or (6) use of concomitant medication that could not
be ceased for the duration of therapy and would result
in significant drug-drug interactions with DAAs. In
addition, patients who would require ribavirin as part of
their therapy were excluded if (1) pre-existing risk fac-
tors for anemia were evident, (2) anemia would be med-
ically problematic, or (3) coronary artery disease or
cerebrovascular disease had been documented and an
acute decrease in hemoglobin up to 4 g/dl as seen with
ribavirin would not be tolerated.
Study assessments
Following randomization, participants complete assess-
ments during the study as outlined in the schedule of as-
sessments (see Fig. 2).
This includes pre-treatment assessment blood tests
and TE, and then a clinical review and blood tests at:
baseline, on treatment at weeks 2, 4, 8, 12, and
post-treatment weeks 12, 24 and 48 weeks, subject to
local national guidelines. The visits post treatment at
week 24 and 48 are to assess for HCV re-infection. TE is
performed pre-treatment and may be incorporated into
an appointment, or may be a stand-alone appointment,
according to the clinic’s usual practice. Detailed ques-
tionnaires are collected at screening and 12 weeks post
treatment. Participants are reimbursed AU$20 at the
screening visit, and AU$40 at the visit 12 weeks post
treatment. Data from assessments is collected on clinical
research forms identified only by study number, and en-
tered into REDCap database at Australian sites, or entered
directly into REDCap database at New Zealand sites.
Data sources
At screening and 12 weeks post treatment, the following
data is collected:
Demographic characteristics including: age, sex, race
and ethnicity, education level, employment status, main
income source, average weekly income, living arrange-
ments, type of accommodation and incarceration history.
Drug use including: history of injecting drug use, fre-
quency and substance injected, presence of injecting
partners, sharing of injecting drug equipment, receipt of
OST, frequency and quantity of alcohol consumed via
the AUDIT-C questionnaire.
Health, wellbeing and quality of life indices as mea-
sured by the following standardized instruments: the
Personal Wellbeing Index, EQ-5D-3 L, 12-item Short
Form Health Survey (SF-12) and Patient Health Ques-
tionnaire (PHQ-SADS).
At 12 weeks post treatment, customer satisfaction data
is collected.
At clinical appointments, the following data is col-
lected: patient-reported adherence to medication, use of
a dosette box, administration of medication by a carer or
Fig. 2 Study schedule
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patient, if on OST (and if so frequency of pick-up),
AUDIT-C questionnaire regarding alcohol, frequency of
injecting drugs and sharing injecting drug equipment,
results of pathology tests, any alteration to medication
regimen and if the participant has received transport or
healthcare worker assistance to attend the appointment.
In addition, data will be collected from the healthcare
services participant failure to attend scheduled study
appointments.
Study outcomes
Primary outcome:
1. The proportion of people attending a PHCS with
chronic HCV who commence DAA therapy at their
PHCS, and achieve SVR12
Secondary outcomes:
2. The difference in the proportion of participants
commencing DAA therapy between group 1
(standard tertiary care arm), and group 2
(intervention PHCS arm)
3. The difference in the proportion of participants
achieving SVR12 between group 1 (standard tertiary
care arm), and group 2 (intervention PHCS arm)
4. To determine the cascade of care for people with
HCV referred to a community hepatitis nurse,
measured by the proportion who (1) complete TE,
(2) complete blood tests, (3) start treatment
(defined as a script being written) and (4) achieve
SVR12. Time between diagnosis, assessment and
treatment will be determined
Sample size and power considerations
We designed a non-inferiority study to examine SVR12
outcomes of people treated in a PHCS, and to estimate
the effect of providing DAA treatment in PHCS on
treatment uptake using intention-to-treat analysis. Prior
to the introduction of PEG-free therapy, approximately
10% of people with HCV who attended a PHCS com-
menced HCV treatment. Of those people, 70% com-
pleted therapy, which had an SVR12 rate of 85% [20].
We estimated that the number of people who com-
menced HCV treatment would substantially increase
with DAA therapy to approximately 50% for people
managed at PHCS, and 30% for people that attend
tertiary hospitals. We attributed most of this difference
to loss to follow-up after referral from the PHCS to the
tertiary hospital, but before tertiary hospital attendance.
We anticipated that 90% would be cured, regardless of
whether they are treated at a PHCS or tertiary hospital,
and that participants would have high levels of
adherence [21].
Based on data from other community cohorts, we esti-
mated 20% of participants would have screening TE re-
sults greater than 9.5 kPa, and would be excluded after
being randomized. Given these response parameters and
equal allocation across study groups, we estimated that
190 study participants were required in each arm in
order to address the primary aim of the study and pro-
vide sufficient power for secondary aims.
Aim 1: To determine if SVR12 outcomes of people
treated in a PHCS are non-inferior to SVR12 achieved by
historic controls.
In keeping with initial DAA trials, our intervention
arm was compared to historical controls [22, 23]. We
hypothesized that the rate of SVR12 in people receiving
DAA treatment in a PHCS would be non-inferior when
compared to an SVR12 rate of 85% for historic controls
treated with PEG, ribavirin and simeprevir. A sample of
76 (50% of 152) participants commencing DAA treat-
ment at the PHCS would give a minimum of 90% power
to show non-inferiority in those receiving DAA therapy
using a 10% margin and an expected SVR12 response of
90% (one-sided α of 2.5%).
Aim 2: To measure the difference in the proportion of
people with HCV infection attending a PHCS who com-
mence DAA treatment, if they are managed at their
PHCS, compared to those who are referred to and man-
aged at a tertiary hospital.
Assuming that 30% of participants in group 1 (stand-
ard tertiary care arm) start treatment, our expected sam-
ple was powered (80%, 5% significance level) to detect
an absolute minimum difference of 16% in treatment ini-
tiation between the arms.
Aim 3: To measure the difference in the proportion of
people with HCV infection attending a PHCS who
achieve SVR12, if they are managed at their PHCS, com-
pared to those who are referred to and managed at a ter-
tiary hospital.
Assuming that 27% of participants in group 1 (standard
tertiary care arm) achieved SVR12, our expected sample
was powered (80%, 5% significance level) to detect an ab-
solute minimum difference of 15.3% between arms.
Aim 4: To use mathematical modeling, informed by
outcomes 1–4, to estimate the reduction in HCV preva-
lence and corresponding epidemiological impact if service
delivery through PHCS was scaled up to a country level.
We hypothesize that the reduced loss to follow-up and
increased treatment uptake when services are delivered
through PHCS will result in greater prevalence reduction
and reduced incidence compared to projections based
on standard tertiary care.
Aim 5: To use mathematical modeling, informed by
outcomes 1–4, to estimate the difference in total health-
care costs, difference in disability-adjusted life years
(DALYs), and incremental cost-effectiveness ratio (ICER;
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AU$ per DALY averted) if service delivery was changed
nationally from the standard tertiary care to PHCS
delivery.
This will be based on existing models that account for
the costs and DALYs accrued as a result of untreated
and progressing liver disease over time [24, 25]. We
hypothesize that PHCS delivery will be cheaper than
standard tertiary care, and result in fewer DALYs.
Statistical analyses
For the primary aim (aim 1), an exact one-sided binomial
hypothesis test will be undertaken to determine
non-inferiority of DAA treatment in PHCS in terms of
SVR12 response. For study aims 2 and 3, given the
individual-level randomized nature of the design, Pearson
chi-square tests [26] of independence will be undertaken
in comparing differences in DAA therapy initiation and
SVR12 across the two study groups. Statistical analyses
will be performed using Stata version 13.0 [27].
Monitoring
The Prime Study’s Steering Committee meets four times
a year to oversee all operational, procedural and policy
aspects of the project. The Steering Committee is com-
prised of gastroenterologists, infectious diseases physi-
cians, senior research fellows, econometricians, a
community hepatitis nurse, and a representative from
AbbVie. The Committee is responsible for reviewing ad-
verse events, and assessing compliance with the study
protocol and with general principles of Good Clinical
Practice.
Amendments to the study protocol
A key challenge for the Prime Study has been to reckon
with the highly dynamic HCV treatment environment in
Australia. During 2015, when the study was being devel-
oped, DAA therapy was not available in Australia out-
side of clinical trials. Recruitment for the Prime Study
initially included only patients with Gt 1, and began in
November 2015. Whilst subsidized DAAs were antici-
pated, it was not known if restrictions would be applied.
In an innovative agreement, the Australian Govern-
ment negotiated a maximum cap on annual payment to
pharmaceutical companies over 5 years, in exchange for
providing DAAs, rather than a fixed payment per patient
treated, resulting in unrestricted access to DAAs for all
Australians living with HCV, effective 1 March 2016. Of
note, the PBS listing of DAAs in Australia enabled all
medical practitioners (including general practitioners) to
prescribe DAAs. The PBS listing of ribavirin-free DAA
regimens to treat Gt 1a, including fixed-dose combination
sofosbuvir/ledipasvir and sofosbuvir and daclatasvir, signifi-
cantly impacted on study recruitment. In Australia, two
thirds of people with Gt 1 have subtype 1a, and one third
have subtype 1b. Recruitment was hampered as study treat-
ment included ribavirin for patients with Gt 1a, whereas ri-
bavirin free DAAs for Gt 1a became available in standard
clinical practice. To facilitate recruitment the protocol was
amended to include participants with Gt 3 and Gt 4 and
the study was expanded to include sites in New Zealand,
where paritaprevir/ritonavir/ombitasvir and dasabuvir ± ri-
bavirin is government funded for all patients with Gt 1,
whilst access to other DAAs is restricted to patients with a
MELD > 15.
In addition, the Australian recommendations for the
management of HCV infection, were published on 1
March 2016 [14]. In response, the exclusion criteria were
amended to align with the Australian recommendations,
changing the TE cut-off from > 9.5 kPa to > 12.5 kPa.
Discussion
To achieve HCV elimination it is critical to increase
treatment uptake, especially amongst PWID. In Mel-
bourne, Victoria the annual HCV treatment rate in
PWID prior to the introduction of DAAs was estimated
to be three per 1000 [28]. Recent modeling data has sug-
gested that increasing treatment uptake to 59 per 1000
PWID annually could achieve the World Health
Organization (WHO) incidence target [24]. For this to
occur, treatment must be more accessible to PWID.
Previous studies have demonstrated that PWID can be
successfully treated in the community [8], and data from
cohort studies indicates that PWID are more likely to
undertake treatment if it is offered in the community in-
stead of a tertiary hospital [10]. In Australia, the propor-
tion of individuals receiving their DAA prescriptions
from general practitioners in 2016 increased from 4% in
March to 19% in September [29]. However, in a recent
survey of European patient groups only 20% had access
to DAA therapy in non-hospital settings, whilst another
European study demonstrated 94% of countries re-
stricted DAA prescribing to specialist physicians only
[30, 31].
Data from the US suggests that primary care physician
prescription of DAAs is highly effective [32]. To our
knowledge, there has been one randomized controlled
trial comparing uptake of directly observed PEG-based
treatment in the community with standard treatment in a
tertiary service [18]. Results of the study supported HCV
treatment in the community, but were limited by the
small sample size (N = 21), and data were not analyzed for
statistical significance.
The reason for the paucity of RCT data to inform
HCV models of care is that such studies are difficult to
perform. As Tait and colleagues recently note in their
description of the Tayside, Scotland experience of the
transition to multidisciplinary care networks “…. it is
very difficult to test the system change and complex
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interventions undertaken here in a randomised trial,
without expensive and large cluster randomised trials,
which are probably impossible to perform” [13]. The un-
precedented rate of policy change has created a challen-
ging research environment. However, the original study
question – does providing HCV treatment in the com-
munity increase retention in care, and treatment uptake,
without lowering the rate of cure? – remains central to
the elimination campaign, nationally and globally.
Whilst conducting a randomized controlled trial of
models of care for HCV is challenging in this period of
unprecedented change in care and treatment, high-quality
evidence is required to shape health services policy that
enables the elimination of HCV globally. Data from the
Prime Study will be presented mid 2018, and will clarify
the role of community-based HCV treatment in the elim-
ination campaign.
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